Role of Rare Molecular Drivers in Cancer Care: A Guide to Personalized Medicine in RET Positive Tumors

April 9, 2022

This CEC Oncology Community Connections educational initiative is targeted to oncology nurses and nurse practitioners attending Oncology Nursing Society (ONS) Chapter meetings across the US. Attendees will gain an appreciation of the latest advances in RET driven cancers (e.g., thyroid carcinoma, NSCLC), including the nurse’s role in comprehensive molecular testing strategies and biomarker-driven treatment approaches. There will be a focus on the expanding role of targeted therapies, particularly as it pertains to rare mutation types, such as RET and discussion on the importance of molecular testing to guide treatment. Activity participants will also explore strategies to improve communication between nurses and patients/caregivers in an effort to promote shared decision-making, reduce adverse events, and improve adherence.

Target Audience

Oncology Nurse Specialists, Registered Nurses, Nurse Practitioners

Learning Objectives

1. Review how molecular drivers can cause tumor proliferation and appraise the importance of appropriate biomarker testing for various tumor types to guide treatment decisions both at diagnosis and upon progression.

2. Appraise the latest testing modalities, such as next generation sequencing (NGS) and liquid biopsy, to identify molecular drivers in various malignancies, focusing on current molecular testing guideline recommendations.

3. Evaluate latest clinical data regarding the efficacy and safety of targeted therapies for the treatment of RET positive tumors in various malignancies, such as NSCLC and thyroid carcinoma and discuss the unique toxicities encountered with these drug therapies.

4. Using a patient-incorporated approach, analyze strategies the oncology nurse can utilize to increase the use of molecular testing guidelines in practice, mitigate barriers to recommended testing, optimize treatment, prevent and treat adverse events, and collaborate with other members of the oncology care team to improve patient outcomes.

Supported through an independent educational grant from Lilly.

Presented by Creative Educational Concepts, LLC.

Additional Information

PDF icon Handout & References2.9 MB
PDF icon General Information642.66 KB
PDF icon LUNGevity Resource533.24 KB
Course summary
Course opens: 
Course expires: 
Event starts: 
04/09/2022 - 10:00am EDT
Event ends: 
04/09/2022 - 11:00am EDT

5 min

Welcome and Introductions/Pre-test

15 min

Exploring the Foundation of Personalized Medicine: The Role of Biomarkers and Molecular Testing in Cancer Treatment

10 min

Evaluating A New Approach to Cancer Management: Recent Data in Targeted Therapies for RET-Positive Malignancies

20 min

Applying the Latest Evidence into Practice: Oncology Nurse Considerations and Patient Conversations

10 min

Conversations with the Experts/Audience Q&A/Post-test


Live Virtual Event
Columbus ONS
10:00AM ET
United States

Victoria Sherry, DNP, CRNP, ANP-BC, AOCNP
Adult Oncology Nurse Practitioner for Thoracic Malignancies
Abramson Cancer Center
University of Pennsylvania Medical Center
Advanced Senior LecturerUniversity of Pennsylvania School of Nursing
Philadelphia, PA

Dr. Sherry is an Adult Oncology Nurse Practitioner for Thoracic Malignancies at the Abramson Cancer Center at the University of Pennsylvania Medical Center in Philadelphia, PA. She is also an Advanced Senior Lecturer at the University of Pennsylvania School of Nursing where she teaches both undergraduate and graduate students. Dr. Sherry attended the Catholic University of America where she obtained her B.S. in Nursing and went on to receive her Masters in Nursing at the University of Pennsylvania. She graduated with a degree as an Adult Oncology Nurse Practitioner. Dr. Sherry went on to obtain her Doctor of Nursing Practice from Duke University where her dissertation focused on distress screening and management in patients with metastatic lung cancer. She is a member of the Oncology Nursing Society (ONS) and the Philadelphia Area Chapter of the Oncology Nursing Society (PACONS). She is also a member of the Xi Chapter of Sigma Theta Tau.

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Victoria Sherry, DNP, CRNP, ANP-BC, AOCNP–has disclosed she is a consultant for AstraZeneca. 

To come.

CEC Staff:
Vanessa Carranza, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Jessica Hall–has no relevant financial relationships to disclose in relation to the content of this activity.

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Nursing (ANCC)
This activity is designated for 1.0 contact hour.

Upon completion of an evaluation and credit request, statements of credit for nurses will be issued automatically.

ONCC/ILNA Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. OCN®, AOCNP®, CBCN®, CPHON®, and BMTCN® nurses may apply 1.0 point in Care Continuum, Diagnosis and Staging, Disease-Related Biology, Oncology Nursing Practice, Professional Practice, Symptom Management, and Treatment categories.

Disclaimer: ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

Supported through an independent educational grant from Lilly.

Presented by Creative Educational Concepts, Inc.

Please login or register to take this course.